Artificial cells, nanomedicine, and biotechnology · 2015
Development of PEGylated solid lipid nanoparticles of pentoxifylline for their beneficial pharmacological potential in pathological cardiac hypertrophy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dhiman Sunny, Mishra Neeraj, Sharma Saurabh
Аннотация
OBJECTIVE: The present study was designed to develop PEGylated solid lipid nanoparticles (SLNs) of pentoxifylline (with increased t½) for the management of cardiac hypertrophy.
MATERIALS AND METHODS: PEGylated SLNs were prepared by melt emulsification method and characterised by zeta potential, polydispersity index, entrapment efficiency, in vitro release and pharmacokinetic profile. Hypertrophy was assessed as increase in tumour necrosis factor-alpha, mean arterial blood pressure, LV protein content and left ventricular end diastolic pressure.
RESULT: PEGylated SLNs (F19) with increased t½ were developed and characterised. F19 attenuates hypertrophy assessed in terms of parameters employed.
CONCLUSION: Thus, PEGylated SLNs (F19) of pentoxifylline have enhanced t½ and consequently more significantly preclude cardiac hypertrophy as compared to pentoxifylline.
MATERIALS AND METHODS: PEGylated SLNs were prepared by melt emulsification method and characterised by zeta potential, polydispersity index, entrapment efficiency, in vitro release and pharmacokinetic profile. Hypertrophy was assessed as increase in tumour necrosis factor-alpha, mean arterial blood pressure, LV protein content and left ventricular end diastolic pressure.
RESULT: PEGylated SLNs (F19) with increased t½ were developed and characterised. F19 attenuates hypertrophy assessed in terms of parameters employed.
CONCLUSION: Thus, PEGylated SLNs (F19) of pentoxifylline have enhanced t½ and consequently more significantly preclude cardiac hypertrophy as compared to pentoxifylline.